- Home
- ZCMD vs SCYX Comparison
ZCMD vs SCYX Comparison
Compare ZCMD & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- SCYX
- Stock Information
- Founded
- ZCMD 2012
- SCYX 1999
- Country
- ZCMD China
- SCYX United States
- Employees
- ZCMD N/A
- SCYX N/A
- Industry
- ZCMD Other Consumer Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- ZCMD Real Estate
- SCYX Health Care
- Exchange
- ZCMD Nasdaq
- SCYX Nasdaq
- Market Cap
- ZCMD 28.5M
- SCYX 28.5M
- IPO Year
- ZCMD 2020
- SCYX 2014
- Fundamental
- Price
- ZCMD $1.11
- SCYX $0.72
- Analyst Decision
- ZCMD
- SCYX
- Analyst Count
- ZCMD 0
- SCYX 0
- Target Price
- ZCMD N/A
- SCYX N/A
- AVG Volume (30 Days)
- ZCMD 178.5K
- SCYX 199.9K
- Earning Date
- ZCMD 01-01-0001
- SCYX 08-07-2025
- Dividend Yield
- ZCMD N/A
- SCYX N/A
- EPS Growth
- ZCMD N/A
- SCYX N/A
- EPS
- ZCMD N/A
- SCYX N/A
- Revenue
- ZCMD $15,864,773.00
- SCYX $2,630,000.00
- Revenue This Year
- ZCMD N/A
- SCYX $410.22
- Revenue Next Year
- ZCMD N/A
- SCYX $248.83
- P/E Ratio
- ZCMD N/A
- SCYX N/A
- Revenue Growth
- ZCMD N/A
- SCYX N/A
- 52 Week Low
- ZCMD $0.95
- SCYX $0.66
- 52 Week High
- ZCMD $2.97
- SCYX $2.28
- Technical
- Relative Strength Index (RSI)
- ZCMD 45.23
- SCYX 46.77
- Support Level
- ZCMD $1.10
- SCYX $0.67
- Resistance Level
- ZCMD $1.24
- SCYX $0.83
- Average True Range (ATR)
- ZCMD 0.07
- SCYX 0.05
- MACD
- ZCMD -0.01
- SCYX 0.01
- Stochastic Oscillator
- ZCMD 0.00
- SCYX 46.35
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.